Slide 1: Cryoport, Inc. First Quarter Earnings Call
Cryoport, Inc. Calendar Year 2017 First Quarter Earnings Call NASDAQ: CYRX May 2017 1
Slide 2: Safe Harbor – Forward Looking Statements
Safe Harbor – Forward Looking Statements This presentation contains certain forward-looking statements that involve risks and uncertainties. Such forward-looking statements include statements regarding attempts to identify new strategic opportunities which may include a strategic transaction, plans
Slide 3: Highlights
Highlights Year-over-year revenue growth 74%; 31% sequentially Impressive revenue growth driven by 139 clinical trials drive revenue as trials progress; 17 in Phase III robust pipeline First commercial biopharma client signed in 2016; two more in 2017 Proven and validated by blue chip clients Advanc
Slide 4: Revenue Trends
Revenue Trends Q1-2017 over Q1-2016 growth: +100% +28% +26% NASDAQ: CYRX May 2017 4
Slide 5: Clinical Trials Drive Revenue Growth
Clinical Trials Drive Revenue Growth Potential Annual Revenue per Trial ($15-75K) ($75-150K) ($200K-1M) ($2M-20M) NASDAQ: CYRX May 2017 5
Slide 6: Kite Pharma Facility
Kite Pharma Facility NASDAQ: CYRX May 2017 6
Slide 7: Kite Pharma Potential Market
Kite Pharma Potential Market NASDAQ: CYRX May 2017 7
Slide 8: Novartis Therapies
Novartis Therapies NASDAQ: CYRX May 2017 8
Slide 9: Trusted by the Life Sciences Industry
9 Trusted by the Life Sciences Industry NASDAQ: CYRX March 2017
Slide 10: Strong and Growing Client Base
Strong and Growing Client Base Biopharma Reproductive Medicine Animal Health NASDAQ: CYRX May 2017 10
Slide 11: Primary Target Market: Regenerative Therapy
Primary Target Market: Regenerative Therapy Inflection point: Commercialization 855 expected to begin in 2017 Ph. I: 270 Launch strategies require scalable (261 in 2016) cryogenic logistics support Clinical trials underway Ph. II: 517 (475 in 2015) Cryoport is the only effective solution Q1 2017(a)
Slide 12: Regenerative Therapy Clinical Snapshot Q1 2017
Regenerative Therapy Clinical Snapshot Q1 2017 • $2.5B raised in Q1 2017 vs $5.1 billion total raised during 2016. Supporting 855 trials as of Q1 855 Trials 2017* • Cold chain logistics spend in support of biopharma is more $2.5B Raised than $10 billion and expected to grow to $13 billion by 2019**
Slide 13: Revenue Trends Q1-2017
Revenue Trends Q1-2017 (quarter ended March 31, 2017) 68% CAGR over the last 4 years - continuing strong double-digit growth year-over-year NASDAQ: CYRX May 2017 13
Slide 14: Strong Revenue Momentum
Strong Revenue Momentum Quarterly Revenue 4-Year CAGR 68% NASDAQ: CYRX May 2017 14
Slide 15: Financial Summary
Financial Summary Statements of Operations Data: (in thousands) 2012 2013 2014 2015 2016 Q1-2016 Q1-2017 Net Revenues $ 863 $ 2,194 $ 3,572 $ 5,525 $ 7,679 $ 1,556 $ 2,712 Cost of revenues 1,761 2,052 2,630 3,847 4,577 974 1,459 Gross margin (loss) (898) 141 942 1,679 3,101 582 1,253 Loss from opera
Slide 16: Financial Metrics Q1-2017
Financial Metrics Q1-2017 (quarter ended March 31, 2017) $1.5M $0.6M Debt 23.9M shares $14.5M Cash Accounts (paid off in April) outstanding Receivable Revenue Supporting 139 Biopharma Gross Margin clinical trials, revenue $2.7M 46% 17 Phase III up 74% up 9PP trials up 100% $0.10 net loss Growth in a
Slide 17: Science. Logistics. Certainty.
Science. Logistics. Certainty. NASDAQ: CYRX May 2017 17
Slide 18: Summary
Summary Year-over-year quarterly revenue up 74%; up 31% sequentially Impressive revenue growth driven by 139 clinical trials drive revenue as trials progress; 17 in Phase III robust pipeline First commercial biopharma client signed in 2016; two more in 2017 Proven and validated by blue chip clients
Slide 19: Non-GAAP Financial Measures
Non-GAAP Financial Measures Note Regarding Use of Non-GAAP Financial Measures This news release contains non-GAAP financial measures as defined in Regulation G of the Securities Exchange Act of 1934. These financial measures are not calculated in accordance with generally accepted accounting princip